Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure

BACKGROUND: Re‐biopsy is important for exploring resistance mechanisms, especially for non‐small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase inhibitors (TKIs). Liquid biopsy using circulating tumor DNA has come into use for this purpose. This retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Zhao, Chao, Zhao, Jing, Wang, Qi, Chu, Xiangling, Li, Jiayu, Zhou, Fei, Ren, Shengxiang, Li, Xuefei, Su, Chunxia, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449239/
https://www.ncbi.nlm.nih.gov/pubmed/30887673
http://dx.doi.org/10.1111/1759-7714.13035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449239/
https://www.ncbi.nlm.nih.gov/pubmed/30887673
http://dx.doi.org/10.1111/1759-7714.13035

Ejemplares similares